MORGAN STANLEY PLC/CALL/STRYKER CORP./430/0.1/20.06.25 Stock

Warrant

DE000ME9BQC0

Market Closed - Börse Stuttgart 14:15:07 2024-05-31 EDT
0.85 EUR -3.41% Intraday chart for MORGAN STANLEY PLC/CALL/STRYKER CORP./430/0.1/20.06.25
Current month-22.02%
1 month-22.02%
Date Price Change
24-05-31 0.85 -3.41%
24-05-30 0.88 -2.22%
24-05-29 0.9 +13.92%
24-05-28 0.79 +2.60%
24-05-27 0.77 -1.28%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 02:15 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying STRYKER CORPORATION
Issuer Morgan Stanley
WKN ME9BQC
ISINDE000ME9BQC0
Date issued 2024-02-27
Strike 430 $
Maturity 2025-06-20 (384 Days)
Parity 10 : 1
Emission price 1.8
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.03
Lowest since issue 0.61
Spread 0.04
Spread %4.30%

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
341.1 USD
Average target price
373.1 USD
Spread / Average Target
+9.38%
Consensus